1. Home /
    2. Altai Protocol Library /
  2. New Protocol: Nivolumab(N)-AVD versus brentuximab vedotin (BV)-AVD in advanced stage (AS) classic Hodgkin lymphoma (HL)

Altai Protocol Library

1041 protocols and counting

All protocols with references and links

All protocols reviewed by a Medical Oncologist/Hematologist

All protocols in major guidelines included

Ability to create your own protocols

Search Library Posts Search
Altai Protocol Library

New Protocol: Nivolumab(N)-AVD versus brentuximab vedotin (BV)-AVD in advanced stage (AS) classic Hodgkin lymphoma (HL)

New Protocol: Nivolumab(N)-AVD versus brentuximab vedotin (BV)-AVD in advanced stage (AS) classic Hodgkin lymphoma (HL)
Study:
  • Phase III, randomized, controlled study (SWOG S1826)
  • Previously untreated pts were ≥12 years (y) with stage 3-4 HL
  • N-AVD (n=489) vs. BV-AVD (n=487)
Efficacy:
  • 1-year PFS: 94% vs 86%, HR:0.48, p=0.0005
  • 1-year OS: 99% vs 98%
Safety:
  • Grade≥3 AEs: Neutropenia (45% vs 24%), anemia (6% vs 9%), peripheral sensory neuropathy (1% vs 8%)

Journal of Clin Oncol 2023 41:17_suppl, LBA4-LBA4

Herrera F A et al. SWOG S1826, a randomized study of nivolumab(N)-AVD versus brentuximab vedotin(BV)-AVD in advanced stage (AS) classic Hodgkin lymphoma (HL).

http://doi.org/10.1200/JCO.2023.41.17_suppl.LBA4

Reviewed by Elvin CHALABİYEV, MD on JUN 10, 2023

Altai Chemo Planner

Quickly Prepare Accurate Chemotherapy Orders

Altai Chemo Planner employs Altai Protocol Library that includes over 1000 chemotherapy protocols for both Hematology and Oncology. You can find major guidelines' protocols, parenteral, and oral, in the library. Altai Protocol Library is frequently and regularly updated.

Learn More